Mark VanArendonk, PhD
Mark VanArendonk has more than 30 years of pharmaceutical experience and specializes in CMC drug development. Through 2013, he was Merck Vice President for Analytical Chemistry in Development and Supply. In this role he was responsible for late stage development programs from IIB through registration, launch and commercialization. Mark served as a founding partner of Garden State Pharmatech, LLC from 2014-2017 and President Vermeer Pharma, LLC beginning in 2018.
As in independent consultant, Dr. VanArendonk supports small and medium-sized companies in early and late development. Most recently he led the CMC team supporting the registration of delafloxacin.
Over his “big pharma” career, through various mergers and acquisitions, Dr. VanArendonk has also worked at Upjohn, Pharmacia and Upjohn, Pharmacia, and Pfizer holding positions of increasing functional and geographical responsibility in Analytical R&D, Quality Assurance, and CMC.
As in independent consultant, Dr. VanArendonk supports small and medium-sized companies in early and late development. Most recently he led the CMC team supporting the registration of delafloxacin.
Over his “big pharma” career, through various mergers and acquisitions, Dr. VanArendonk has also worked at Upjohn, Pharmacia and Upjohn, Pharmacia, and Pfizer holding positions of increasing functional and geographical responsibility in Analytical R&D, Quality Assurance, and CMC.